U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ...

The U.S. FDA granted accelerated approval to Bristol Myers Squibb's ZENBEXUS (iberdomide), the first CELMoD therapy, in combination with daratumumab, hyaluronidase-fihj, and dexamethasone for treatment of multiple myeloma patients after at least one prior therapy. Approval is based on phase 3 trial results showing doubled minimal residual disease-negative complete response rates versus prior standard of care.

This Wire brief sits within Fusion42's coverage of Biotech, and 12 sources have reported it between 13 Aug 2026 and 17 Aug 2026.